NEW YORK, April 23, 2021 /PRNewswire/ -- MindMed (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, announced today that the Company's subordinate voting shares have been approved for listing on The Nasdaq Capital Market ("Nasdaq"). Trading is expected to begin on Tuesday, April 27, 2021, under the symbol "MNMD" on the Nasdaq. MindMed will retain its listing on the Neo Exchange Inc. under the symbol "MMED" and the Company's subordinate voting shares will continue to trade on the OTCQB under the symbol "MMEDF" until trading on the Nasdaq commences. "The listing of our stock on the Nasdaq represents a significant milestone in our growth as a publicly-traded company," said J.R. Rahn, CEO and Co-Founder of MindMed. "We believe this listing will increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value. I would like to thank our employees, management, directors and our many collaborators for their hard work in making MindMed a member of the Nasdaq exchange, an important step that will help facilitate our mission to discover, develop and deploy psychedelic inspired medicines and therapies to address addiction and mental illness." About MindMed MindMed is a clinical-stage psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies. MindMed trades on the Canadian exchange NEO under the symbol MMED and in Germany under the symbol MMQ. MindMed will commence trading on the Nasdaq under the symbol MNMD effective April 27, 2021; until then the Company will continue to trade in the United States under the symbol MMEDF on the OTCQB.
Psyched: First Psychedelics ETF Comes To The US, Bills Move Forward In Texas, California and New York 6:51 am ET June 7, 2021 (Benzinga) Print Psychedelics ETFs Are Gaining Traction Defiance ETFs launched the “Next Gen Altered Experience ETF,” the first U.S.-listed ETF that zeroes in on the psychedelics industry. The fund went public on the NYSE Arca exchange under the ticker “PSY,” carrying net assets of around $2.59 million distributed between psychedelics and cannabis companies. A passive ETF, PSY follows the BITA Medical Psychedelics, Cannabis and Ketamine Index. Sylvia Jablonski, CIO of Defiance, said the companies included need to fulfill the minimum requirements established by SEC regulations for ETFs in the U.S., thus a number of low market-cap companies had to be left out. “We have every pure company that does psychedelics research in our ETF that has a 70 million market cap and a five hundred average daily volume,” said Jablonski, speaking on a panel at the virtual Benzinga Cannabis Capital Conference on Friday. PSY carries 21 companies, out of which 35% are psychedelics companies, including Compass Pathways (NASDAQ: CMPS), MindMed (NASDAQ: MNMD), Numinus (TSXV: NUMI) Cybin (NEO: CYBN) (OTCQB: CLXPF), Field Trip Health (CSE: FTRP) (OTCQX: FTRPF) and Red Light Holland (Canada: TRIP) (OTC Pink: TRUFF). The remaining 65% is covered by companies in the medical cannabis space. “As soon as other [psychedelics] companies get further investment and to a point where they can comply with the rules, we’re definitely going to include them. Our goal is to have the purest psychedelics ETF out there,” Jablonski said.
Been in this since 0.39 and I have been expressing this is going to be a block buster. This is still early and will only grow from here. Lot's of fantastic things going on with this company. Some major speculation on this stock is a possible short term partnership with J&J: A Study to Assess 18-Methoxycoronaridine https://www.clinicaltrials.gov/ct2/show/NCT04292197?lead=Mind+Medicine,+Inc.&lead_ex=Y&draw=2&rank=1 The current contact for this trial is listed as: Rob Barrow... he replaced the contacts below who were originally listed on the Trial Data when this PR dropped on Feb. 2, 2021... which makes sense since he is the Business Development Officer: https://www.prnewswire.com/news-rel...tal-medicines-and-therapeutics-301219840.html --- The ORIGINAL contacts on this trial work for Janssen Pharmaceutical Companies were: Jason Summa - https://www.linkedin.com/in/jasonsumma/ Jason Left J&J in August 2020 Jamie Freedman - https://www.linkedin.com/in/jamie-freedman-0543104/ Jamie is still at Janssen and assume involved with this trial as she was on it originally You can proof this by looking at the revision history of the Trial... Look at Version 5 of the document. https://www.clinicaltrials.gov/ct2/history/NCT04292197?V_5=View#StudyPageTop Both of these folks are tied to Johnson & Johnson via Janssen... I don't think that is a coincidence. They are working with Linear Clinical Research Ltd in Australia / Perth. According to the website: Australian (TGA) clinical trial start-ups are typically 4-6 months faster than US (FDA) trials. Better still, they’re much cheaper – often a third of the cost and exceptional quality. No IND required Fast-tracked approvals Generous R&D refunds Excellent health system Access to patient databases Data accepted by FDA, EMA, CFDA & PDMA --- Looks like to me they will fast track in Australia - then partner with J&J if successful.
Russell US Indexes Reconstitution ftserussell.com June 4, 2021 Russell 3000® Index – Additions https://content.ftserussell.com/sites/default/files/russell_3000_index_additions_-_2021.pdf
as for the drug itself if i'm going to do acid i prefer to get the benefit of hallucinating with it. but, hey, if this helps people without trippin' i'm happy for em.
There is a therapeutic use for everything... this is no different. Some people are terrified of what it could do so this will alleviate certain fears. Bottom line... it works very well anecdotally. Looking forward to this one growing.
Forbes - Deepak Chopra On MindMed Partnership, How Psychedelics Influenced The Trajectory Of His Life https://www.forbes.com/sites/davidc...d-the-trajectory-of-his-life/?sh=4aa53b9620d8
Why the North America Psychedelic Drugs Market is Expected to Grow With the Fastest CAGR for Next Several Years https://www.prnewswire.com/news-rel...st-cagr-for-next-several-years-301307426.html
Remember this when bashers show up about how the compounds we are working with are not patentable… Those are classic and stage 2 drug candidates at best and have their place in ceremonial and ethogenic uses. MindMed will develop derivatives of these and patent those. No different than what Purdue did by basically replaced the MeO groups with MeCOO in heroin and created a legal drug deal. Things will be similar in fashion with new drugs that in my opinion are needed much more than pain meds. By the way fuck Purdue and the shit fest they caused for loved ones of mine and yours. Psychedelics are not habit forming. Huge upside… Look at aspirin — it’s salicylate acid which is not patentable- it’s a plant protein. Yet Bayer advanced it to acetylsalicylate acid and then ran forward… Point is they will upgrade these molecules for the benefit of mankind and it will work. Whether they are around in 20 years is up for debate but I’m in the wave and will ride this out… I grew up with a chemist as a father so what the hell do I know expect for the fact we are about to make a lot of cabbage when this gets dialed in.
that, i believe is true. it's been 35 years since i touched the stuff and surely it has evolved since then, but, back then it was actually scary. never knew where the trip would take you and if it would actually ever wear off. not for the weak minded for sure.
MindMed on Mad Money… tomorrow should be interesting. https://mobile.twitter.com/MadMoneyOnCNBC/status/1404947740673593346
Jamie Freedman on MindMed Team?! https://mindmed.co/team/jamie-freedman/ I wasn't aware she had joined MindMed. She was part of the Janssen R&d team that were originally the main contacts for MindMed 18-MC trials. Look at this post for more information and connection back to J&J... --- https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163428763 18-MC Trial - Connecting the Dots to J&J - Updated & Revised A Study to Assess 18-Methoxycoronaridine https://www.clinicaltrials.gov/ct2/show/NCT04292197?lead=Mind+Medicine,+Inc.&lead_ex=Y&draw=2&rank=1 The current contact for this trial is listed as: Rob Barrow... he replaced the contacts below who were originally listed on the Trial Data when this PR dropped on Feb. 2, 2021... which makes sense since he is the Business Development Officer: https://www.prnewswire.com/news-rel...tal-medicines-and-therapeutics-301219840.html --- The ORIGINAL contacts on this trial work for Janssen Pharmaceutical Companies were: Jason Summa - https://www.linkedin.com/in/jasonsumma/Jamie Freedman - https://www.linkedin.com/in/jamie-freedman-0543104/ You can proof this by looking at the revision history of the Trial... Look at Version 5 of the document. https://www.clinicaltrials.gov/ct2/history/NCT04292197?V_5=View#StudyPageTop Both of these folks are tied to Johnson & Johnson via Janssen... I don't think that is a coincidence.
They likely have good connection to them and the fact that J&J was a major part of the biggest issues with opiods they have a good reason to build good PR with 18-MC Watch this documentary and you will see why 18-MC is going to be a big thing in the near future. https://www.hbo.com/documentaries/the-crime-of-the-century
MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company NEWS PROVIDED BY Mind Medicine (MindMed) Inc. Jul 08, 2021, 08:20 ET SHARE THIS ARTICLE MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, and Datavant, Inc. ("Datavant"), a leader in helping healthcare organizations safely connect their data, announced a partnership through which MindMed will use Datavant's privacy-protecting technology to link MindMed's clinical trial data to external data from both clinical and real-world sources. MindMed plans to use Datavant's linking technology across various stages of the drug lifecycle including discovery, clinical development, and commercialization. Data linking will allow MindMed to create broad and detailed datasets to better understand the real-world treatment, service utilization, and healthcare experiences of patients with psychiatric and substance use disorders. This data, and the deeper understanding of both the relevant illness and the paths of care through which patients proceed, will help enhance MindMed's clinical trial planning, execution, and preparation for commercialization of its novel molecules. "Data fragmentation today prevents organizations from understanding how innovative therapies can be used to improve patient outcomes," said Travis May, Chief Executive Officer of Datavant. "The ability to safely connect data from across the healthcare ecosystem to understand the safety, efficacy, and access to a variety of therapeutic interventions creates the opportunity to greatly improve outcomes in psychiatry and addiction medicine." "While MindMed pursues its mission of radically transforming the paradigm of care for treating psychiatric and substance use disorders, the goal of this initiative is to accelerate efforts to build better psychedelic-inspired medicines and adjacent therapeutic technology", said Robert Barrow, Chief Executive Officer of MindMed. Daniel R. Karlin, MD, MA and Chief Medical Officer of MindMed, added, "In order to build a deeper understanding of the illnesses we seek to treat, we need to better integrate data on the efficacy and efficiency of existing care models as well as patient and provider-related outcomes. Clinical trials capture a small window of time in a patient's overall experience of their illness. These trials, while essential for drug development, tell us nothing about patients' access to, and use of, various treatment modalities through time. Truly understanding the patient journey by knowing about all relevant encounters and events that lie outside of the limited window of clinical trials will enable us to better develop and deploy therapeutics that offer new hope for people who are suffering." About MindMed MindMed is a clinical-stage biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic inspired medicines and therapies. MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ. For more information: www.mindmed.co About Datavant Datavant's mission is to connect the world's health data to improve patient outcomes. Datavant works to reduce the friction of data sharing across the healthcare industry by building technology that protects the privacy of patients while supporting the linkage of de-identified patient records across datasets. Datavant is headquartered in San Francisco. Learn more about Datavant at www.datavant.com.
Huge MindMed DD From Stansberry Research In this month's issue of *Cannabis Capitalist*, *we're* going to be the "suckers"... albeit educated ones. It may lead to big gains and help us avoid losses by recognizing a pattern that shows up across all disruptive technologies and trends. Last month, we showed you a list of companies that we're watching closely in the emerging medical sector of psychedelic therapies. This new trend has real potential to disrupt how we treat and potentially cure mental illness. Early research – both anecdotal and peer-reviewed – is showing tremendous promise. But this is just getting started. Like medical cannabis, we believe this new therapy will follow a similar pattern for information, medical use, and investment. And this month, we're recommending **MindMed (Nasdaq: MNMD)** from that watch list. But first, let's see why this pattern is so important when it comes to investing in disruptive markets... #### The 'Sucker's Rally' That Follows Innovation Cannabis investors made great returns in the early days of the sector. Stocks soared to incredible valuations, but later came crashing back down. Then, they repeated the pattern. Now, there are a number of well-financed and managed cannabis businesses in the U.S. that are on their way to much higher valuations. They're driven by fundamentals rather than just hype. You can see it in our portfolio, as we have five open positions (out of 13) up more than 100%. What drives this early rally followed by a crash (or two) and then on to big, legitimate gains? There is a boom-and-bust cycle in almost every emerging industry that has the potential to disrupt how things are done. We call the first run-up the "sucker's rally." It occurs swiftly as mainstream and social media begin to cover the news about a new, innovative industry. Investors begin to pile into any stocks that resemble the emerging sector. The fundamentals of the businesses don't matter. The sucker's rally is a speculative frenzy... and it can't last. *But it's a great time to make money, provided you prepare for the next phase...* The rally is followed by a tremendous crash. This is when cooler heads prevail. Investors begin to do fundamental analysis. They put pen to paper and often conclude that the stocks are tremendously overvalued and won't offer revenue or profit for years. And that's the time to take a step back from the sector for a bit. My friend and former hedge-fund manager Whitney Tilson famously called the top of the sucker's rally in cannabis. He highlighted Tilray shares at $300 in September 2018. A year later, the shares had declined 90% and ultimately fell by a stunning 99%. As the companies in the bunch with real fundamentals make progress, the cycle continues. The sector reaches another tipping point, but at much lower valuations. Investors begin to get excited again. This time, their enthusiasm is fueled by fundamentals. This is the start of the next phase... the "mega boom." It often lasts for years, or even decades, as the underlying innovations take root, evolve, and become the next big thing. This is the time to own these stocks for the long term. We believe a mega-boom is happening across the spectrum of health care. You can see it in things ranging from cancer-drug development to digital health care that was accelerated by the pandemic. And we will eventually see it in psychedelic-drug therapies offering radical solutions in mental health... Global research and advisory firm Gartner Research calls this pattern a "hype cycle." You can see it play out in a few different sectors that are just a small sample of the many times it has been studied and documented... **Green-Energy Boom** About 15 years ago, the pro-environmental movement was really hitting its stride. The green-energy boom was off to the races. Billionaire T. Boone Pickens made a fortune in the Texas oil business. However, much of his net worth came in the early-to-mid 2000s – in green energy. He pivoted to the green-energy wave through wind-energy investments in a big way, determined to end U.S. dependence on the Middle East for oil. His interest in the idea got investors really excited. ?? But Pickens had a problem. Wind-energy technology was nowhere near mature enough to move the needle. Environmentalists worried that big windmills could actually disrupt the environment. There were holes in the story – technological, financial, and cultural. Solar energy was the same story. But these holes did not prevent a massive rally in green-energy stocks. In the chart above, the S&P Global Clean Energy Index illustrates the sucker's rally followed by a giant crash. Eventually, industrial footing and traction took hold. The index has more than tripled off the bottom and is likely beginning a long-term increase in value. **Cryptocurrency Craze** Created after the financial-market meltdown in 2008 to 2009, bitcoin has followed a similar path. It was worth less than a penny back then, and jumped to $0.08 in 2010. But the real rally came in 2017 as cryptos gained attention and perceived relevance. Elon Musk and other influencers began to speak about the crypto publicly. Even famed investment manager Bill Miller put 30% of his fund in bitcoin. ?? The coin went from essentially zero to worth $20,000 before ending the following year down about 80%. However, bitcoin had proven itself to be part of the global financial fabric at that point. In the coming years it bounced around between $5,000 and $10,000. Then in 2021, the value soared to $60,000 per coin. This new investment instrument is now part of our financial world. Our own crypto expert Eric Wade writes *Crypto Capital*. Given his views, cryptos may still be early into their mega-boom. **The Dot-Com Boom** Do you remember back in the early days of the Internet? It was going to change everything. And investors all wanted in on the action. Capital flowed into this new way of life. Companies were created and went public overnight. Businessmen like Mark Cuban became billionaires. And then it all came crashing down... But the early promise of the Internet has played out. It *has* changed almost every aspect of our lives. The mega-boom began about eight years after the crash. The survivors flourished – real companies with revenue, earnings, and evolved innovation. ?? The tech-heavy Nasdaq is now almost three times the value of the sucker's-rally peak. **And of Course... Cannabis** The subject matter of this investment newsletter has followed the same pattern. It has had a couple sucker's rallies and one big blowup. Now, as the sector has had room to mature, it's in the early stages of a mega-boom. ?? Related to medical cannabis is the promising new therapeutic use of psychedelic drugs. Below is an index of 58 publicly traded stocks vying for position in this disruptive emerging market. ?? While some peaks have occurred, we do not believe a true sucker's rally has happened... and it may be around the corner. Psychedelics are about to begin the hype cycle. As we said last month, the successful use of psychedelic drugs as an alternative to failed traditional therapies is going mainstream. Research is being published from places like Johns Hopkins University School of Medicine and the *New England Journal of Medicine*. The massive global market in mental illness will cost $16 trillion by 2030. In the U.S. alone, the measure of the direct and indirect costs for mental illness and substance abuse (which often go hand in hand) adds up to about $713 billion ($113 billion for mental health and $600 billion for substance abuse). We want to own a stock with real potential, lots of cash, supportive investors, and a ticker traded on a U.S. exchange as the hype cycle begins. And that brings us back to MindMed. This is a little company with big ambitions. A handful of people we've talked to believe this could be the bitcoin of psychedelics. And we want to be on board for the ride up once investors start piling into the sector. Keep in mind, we believe the sucker's rally is coming... which means this is a speculative, shorter-term trade. These stocks will be very volatile. In other words... don't put your rent money into this investment. #### A Strong Candidate to Win Out in the Speculative Frenzy MindMed is a $1.1 billion company focused on mental-health disorders, including anxiety, depression, and substance-use disorder. Its studies involve LSD, MDMA, psilocybin (the hallucinogenic compound in "magic mushrooms"), and other psychedelic compounds. The company is led by a group of innovative researchers with decades of drug-development experience. It is partnered with New York University's Langone Medical Center, University Hospital Basel in Switzerland, and Maastricht University in the Netherlands, greatly expanding the clinical reach of the organization. We believe a number of near-term catalysts may move the shares higher over the next 12 months and create a speculative frenzy in its shares (as well as others in the psychedelic-therapy space). We like MindMed for four reasons: * The company is well-financed with plenty of cash. * Current research projects are showing promise, leading to catalysts that may increase demand for the shares. * Shares trade on the Nasdaq, opening it up to a broad investor base. * An interesting addition to the company's scientific advisory board directly links the company to Big Pharma. #### Plenty of Runway In mid-May, the company reported its first-quarter financial results for 2021. In addition to a lot going on clinically, the company reported $160 million in cash. Two recent financings supported the cash levels – a vote of confidence from investors. The first was a formal financing that added $73 million and was upsized from original levels. The second was a $15 million private placement. Investors are clearly interested in this company... Since 2019, the company has raised $204 million from seven different financing rounds. The company looks to be burning about $14 million per quarter in cash. However, that is likely to increase with research activities. #### Lucy, Flow, and Layla Could Spark a Rally MindMed has a lot going on. However, we would highlight three research efforts in the pipeline with promise. Each has its own name, which is common in drug development. **First is Project Lucy**. MindMed acquired this clinical trial from University Hospital Basel in Switzerland. This project uses LSD to treat anxiety disorders and is the most advanced of these projects from a clinical-trial timeline perspective. Patients will be given a single dose of LSD in a protected, safe setting while a therapist guides the patient through the experience. This is a common approach being studied in many places. Two doctors from University Hospital Basel with experience in psychedelic-drug research run the trial and are partnered with the company. This deal provides MindMed with critical expertise. An Investigational New Drug ("IND") application – which MindMed expects to file in the third quarter of 2021 – is being prepared for the Food and Drug Administration. An IND grants a pharmaceutical company permission to begin human trials. It also permits the substance under study to be transported across state lines. This is important, as LSD is an illegal substance per the U.S. federal government and many other countries. Approximately 200 patients across 20 U.S. sites will be involved in the study, which is expected to commence in early 2022. The anxiety-medication market is huge – with $4.7 billion spent annually. There will likely be some fanfare around this milestone that could move the stock higher. **Project Flow** is looking at the concept of micro-dosing of LSD and the beneficial effects that may result. Anecdotally, LSD and psilocybin have been shown to lessen anxiety and increase focus. Both are being researched globally for mental-health issues. This study is similar to Lucy, but the dosing is different. Micro-dosing means using very small amounts of the drug under study. The amounts used will not cause any hallucinogenic effects for the patient. Patients will be given 20 micrograms of LSD every three days for six weeks. They will then be followed for 18 to 24 months. As an aside, the term "micro-dosing" is somewhat nonsensical. When you take two aspirin for a headache, you are essentially micro-dosing aspirin and not taking the whole bottle. Studies are simply experimenting with different dose levels. This project will begin Phase II during the third quarter of 2021. It is being conducted at two sites – the Netherlands and Basel, Switzerland. This is essentially a proof-of-concept study, but could be another catalyst that sparks investor interest. **Project Layla** is looking at opioid withdrawal and substance-use disorder. The goal is to mitigate withdrawal symptoms so that patients do not relapse to addiction. MindMed is hoping to do this by stabilizing dopamine levels in the brains of opioid addicts using a synthetic molecule derived from ibogaine – a naturally occurring psychoactive substance found in the iboga plant in the African rainforests. In high doses, pure ibogaine can cause heart failure. However, the company has altered its molecule to maintain all of the perceived positive attributes of the substance without the detrimental effects. The opioid epidemic in the U.S. and abroad is a major public-health issue. Overdoses from opioid addiction even caused life expectancy to decrease in the U.S. over the past years. Globally, $5.8 billion is spent on anti-addiction medicines. This trial is being conducted in Australia and finishing Phase I this year. No excess toxicity has been observed, and the study is expected to move into Phase II in early 2022. An estimated timeline suggests observations will be available over the next two years and conclude in 2024. In addition to these trials, the company – through its academic partnerships – is working on a number of other research projects. It is licensed for DMT, MDMA, LSD, and psilocybin. This work is expected to source the next round of commercially viable research. And if you'd like a refresher on the different psychedelic substances, see our [June 2021 issue here](https://members.stansberryresearch.com/articles/a-psychedelic-primer-for-the-next-1000-gainer). #### Albert – The Digital Division Albert is what MindMed is calling its digital health care effort. This is particularly interesting to us. Digital health care has been fully accepted and legitimized by the global COVID-19 pandemic. In the past 10 years, more than $40 billion has been invested in startups using digital solutions to address all kinds of health care needs. MindMed has created this division to complement its clinical research. Specifically, the user-friendly interface will help with connecting patients to psychiatric clinicians, managing clinical trial data, remote patient monitoring, and medication adherence regimens. Moreover, recent software-driven partnerships have been developed with the National Institutes of Health, Merck, Novartis, and others. These may lead to near-term revenue opportunities. #### MindMed Trades on a U.S. Exchange On April 21, 2021, MindMed began trading on the Nasdaq. As we've discussed with our cannabis stock picks, getting listed on a major U.S. exchange is a massive catalyst. For example, **GrowGeneration (Nasdaq: GRWG)** was trading around $6 a share when we recommended it. Its listing on a major exchange opened it up to a wide audience of investors. And as the legal cannabis market in the U.S. exploded, so did GrowGeneration. Since inception, shares are up eightfold. Because of its U.S. listing, we believe MindMed will be a go-to stock for investors looking for exposure to the psychedelic-drug market. This will give the full breadth of the market the opportunity to trade in the stock and push it higher. An added benefit is analyst coverage. Since making the move to the Nasdaq, MindMed management suggested to us that analysts have started to work on initiation reports – the first report written on a company by analysts. This tells the investment world that this analyst will now be following the stock on a regular basis. It is almost a ceremonial process with Wall Street research. We expect more analysts to be saying good things about this stock soon. That could also be a near-term positive catalyst. #### A Trade Based on Near-Term Catalysts There is not much to talk about in terms of revenue and earnings. If that sounds crazy – it is. I've spent my career doing fundamental analysis and picking stocks on that basis. Market psychology, chart patterns, and near-term catalysts play a part, but they are secondary factors. Ultimately, revenue and cash flow will win out. However, we must also recognize the ability to make big returns based on the secondary items mentioned above. These things drive big run-ups in stocks for disruptive innovation. This is where we are in psychedelics right now. The fundamentals will build in coming years. I'm sure of it. For now, we are looking for company characteristics that will drive the sucker's rally in psychedelic stocks and pick a winner. Cash on the balance sheet and a history of supportive investors is a critical factor. We have both with MindMed. #### What Could Go Wrong? Risks abound with this recommendation. By now, we hope you've gotten the message loud and clear. However, here are four fears that might cause us to lose money near term. **First – did the sucker's rally already happen in this stock?** In September 2020, the shares traded around $0.30 to $0.45 per share. That month, two catalysts occurred: In an "aptly timed" move, Canaccord Genuity initiated coverage of the stocks with a "Speculative Buy" rating. A week later, the company announced it would seek listing on the Nasdaq. From that point, shares have traded as high as $4.69. This is more than 10 times the price less than a year ago. We are OK with this run-up, as it's early and looks to be company specific. Shares are off about 29% from those levels. This run-up is missing key parts of a sucker's rally – namely, accelerating coverage of psychedelics in the news. That has only just begun. **Second – near-term catalysts could prove to be negative**. Milestones from the three projects we discussed above may not meet their goals. That could cause us to lose a lot on this stock. It would be like a biotech company releasing bad news about a drug in development. **Third – there are few fundamentals to fall back on**. As mentioned above, revenue and earnings are not part of the thesis here. We believe investor frenzy will kick off the hype cycle and drive shares to soar. That said, we are keeping a close eye on cash levels and expected burn rates. **Fourth – the CEO just resigned**. On June 9, MindMed announced the departure of its CEO and founder, JR Rahn. Taking his place will be Chief Development Officer Robert Barrow. Rahn founded the company and was successful in achieving a number of early-stage milestones. As the company matures and research moves into later-stage trials, it needs new expertise. In the meantime, Barrow is an accomplished pharmaceutical executive with over a decade of experience. While management change in the C-suite can signal trouble, it is also a natural progression for early-stage companies. That is what this appears to be. Moreover, this change can also be seen as positive. The company, its founder, and its board proactively recognize the need to change leadership. That is required to move the company forward. #### Despite the Risks, Let's Own Some MindMed We believe a drug-development revolution is upon us with psychedelic drugs. The broad legalization of cannabis is supporting the move. And the medical benefits of psychedelics may even outstrip cannabis. Don't get me wrong, medical cannabis will see many breakthroughs. However, the specific use targeting mental health – and positive results realized by this potential new class of drugs – is astounding. As more peer-reviewed, randomized, double-blind clinical trials show results, the sector will continue to gain publicity and attention. Another part driving a rally in these stocks could be M&A from traditional biotech and Big Pharma competitors. For example, ketamine-derived Spravato is already out there for treatment-resistant depression. It is owned by the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ). Others are likely watching the psychedelics trend very closely. There's also another very interesting datapoint supporting this stock: Dr. Peter Bergethon has joined the company's Scientific Advisory Board. This is noteworthy for two reasons. First, he is an expert in neurology, digital medicine, and central-nervous-system drug development. His input will be invaluable to the company. Second, his day job is with $57 billion biotech company Biogen. Bergethon is the vice president and head of Digital and Quantitative Medicine. Biogen has been working hard on therapies for Alzheimer's disease, among others. Bergethon could be a direct connection to Biogen as a strategic partnership for MindMed. This might include specific projects, research, or a buyout. All of this will eventually spark a "sucker's rally" in this emerging part of the health care sector. And we want to be on board when that happens. --- 18-MC Trial - Connecting the Dots to J&J - Updated & Revised A Study to Assess 18-Methoxycoronaridine https://www.clinicaltrials.gov/ct2/show/NCT04292197?lead=Mind+Medicine,+Inc.&lead_ex=Y&draw=2&rank=1 The current contact for this trial is listed as: Rob Barrow... he replaced the contacts below who were originally listed on the Trial Data when this PR dropped on Feb. 2, 2021... which makes sense since he is the Business Development Officer: https://www.prnewswire.com/news-rel...tal-medicines-and-therapeutics-301219840.html --- The ORIGINAL contacts on this trial work for Janssen Pharmaceutical Companies were: Jason Summa - https://www.linkedin.com/in/jasonsumma/Jamie Freedman - https://www.linkedin.com/in/jamie-freedman-0543104/ You can proof this by looking at the revision history of the Trial... Look at Version 5 of the document. https://www.clinicaltrials.gov/ct2/history/NCT04292197?V_5=View#StudyPageTop Both of these folks are tied to Johnson & Johnson via Janssen... I don't think that is a coincidence. They are working with Linear Clinical Research Ltd in Australia / Perth. According to the website: Australian (TGA) clinical trial start-ups are typically 4-6 months faster than US (FDA) trials. Better still, they’re much cheaper – often a third of the cost and exceptional quality. No IND required Fast-tracked approvals Generous R&D refunds Excellent health system Access to patient databases Data accepted by FDA, EMA, CFDA & PDMA --- Looks like to me they will fast track in Australia - then partner with J&J if successful.
Stanley Glick 18-MC interview from 6 years ago... Remember this is before MindMed... something incredible is ahead folks. --- Our guest this evening is Stanley D. Glick , Ph.D. , M.D., Professor Emeritus at Albany Medical College, who will be talking about his research on ibogaine and the ibogaine congener 18-MC (18-Methoxycoronaridine) and their potential as anti-addiction drugs. https://www.blogtalkradio.com/harm-reduction/2015/07/31/ibogaine-18-mc-and-addiction
MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes NEWS PROVIDED BY Mind Medicine (MindMed) Inc. Sep 02, 2021, 07:30 ET SHARE THIS ARTICLE MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, and BioXcel Therapeutics, Inc. ("BioXcel"), a leading clinical-stage biopharmaceutical company, announce the publication of BioXcel's International Patent Application No. PCT/US2020/051256 (published as WO2021055595) for detecting and preventing the early onset of agitation in patients predisposed to highly agitated behaviour. The disclosure provides a method for measuring the signs of an impending agitation event and alerts the caregiver to treat the subject before agitation symptoms arise. Agitation is not an independent illness, rather it is a symptom of many acute and chronic neurological and psychiatric conditions. Agitation is characterized by excessive motor or verbal activity, irritability, uncooperativeness and, in some cases, can escalate to aggressive or even violent behavior. Agitation is a frequent driver of emergency care and can lead to physical injury to patients and caregivers. When severe or repetitive, agitation can lead to the need for facility-based care of individuals who could otherwise be cared for at home. Tracking agitation and patterns of behavior could allow earlier efforts to de-escalate, earlier dosing of medication, and reduce the need for more intensive intervention. The MindMed-BioXcel collaboration and this patent application seek to measure signs of an impending agitation event, alert caregivers, and identify optimal treatments. Martin Majernik, MindMed's Director of Digital Product Lifecycle, added, "This collaboration hits close to my heart because the first subject who helped us develop prototypes was my now deceased grandfather, while he was in his later stages of dementia. Watching him become increasingly confused and ultimately become aggressive was heartbreaking for our family, yet through this project, that heartbreak was sublimated into motivation for me. Fortunately, through this project, our exceptional team of clinicians and engineers is dedicated to building products that can have a tangible impact." Dr. Daniel R. Karlin, MindMed's Chief Medical Officer added, "This project serves as an example of the kind of impact that can be achieved at the cross-section of digital medicine, applied machine learning, and traditional development of pharmaceutical compounds. The early detection of any clinically important symptom can bring significant value to patients across a range of conditions." The published patent application describes a method to collect digital measures that reliably predict emergence of agitation. The system continuously monitors physiological and behavioural correlations of sympathetic nervous system activity in patients, using an automated sensor placed or mounted on the subject's skin surface. The described method also alerts a caregiver to an impending agitation episode in a subject. The patent application also outlines a treatment component whereby the patient with emerging agitation is provided an anti-agitation agent and guided behavioural management to prevent the worsening of an agitated episode. About MindMed MindMed is a clinical-stage biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic inspired medicines and therapies. MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ. About BioXcel BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. Forward-Looking Statements Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "will", "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe", "potential" or "continue", or the negative thereof or similar variations. Forward-looking information in this news release include, but is not limited to, statements regarding the success of an application stemming from the international patent application, accuracy of the published patent application's results, the effectiveness of the patent application's findings on agitation, the ability to accurately monitor clinical subjects, episodes of agitation and behaviour, ability to accurately predict physiological and behavioural correlation, the successful implementation of results to various subjects and the ability to utilize the a patent stemming from the international patent application. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described under the headings "Risk Factors" in the Company's filings with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company's profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from those anticipated in such information. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information. Media Contact: [email protected] SOURCE Mind Medicine (MindMed) Inc. Related Links mindmed.co
MindMed Appoints University of North Carolina Psychiatrist and Pharmacologist Dr. Bryan Roth to Scientific Advisory Board https://www.prnewswire.com/news-rel...h-to-scientific-advisory-board-301387396.html NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the addition of Bryan L. Roth, MD, PhD to its Scientific Advisory Board. Dr. Roth has spent over 30 years studying molecular neuropharmacology. He is the Michael Hooker Distinguished Professor in the Department of Pharmacology at the University of North Carolina's (UNC) School of Medicine. He is also the director of the National Institute of Mental Health Psychoactive Drug Screening Program. Dr. Roth's research focuses on removing the hallucinogenic effects from psychedelic drugs; eliminating the hours-long hallucinatory trips that may turn some patients away from psychedelic-assisted treatments. He was among the first to publish in the scientific journal, Cell, the structure of how LSD binds to serotonin receptors within the brain. This structure is crucial to help scientists understand why psychedelics can have hallucinogenic and therapeutic effects. Dr. Roth's search for drugs that bind to and activate serotonin receptors without causing a psychedelic experience secured a $27 million grant from the Defense Advanced Research Projects Agency, a research and development agency of the US Department of Defense that helps advance emerging technologies. The grant helped fund Ultra Large-Scale-Docking, a computer program which can generate a billion theoretical psychedelic compounds that all score differently in how they activate the 5-HT-2A serotonin receptor. Dr. Roth's team is studying the compounds Ultra Large-Scale-Docking identifies which are the likeliest to activate the serotonin receptor without triggering hallucinations. MindMed CEO Robert Barrow said, "We are thrilled to welcome Dr. Roth to our Scientific Advisory Board. In the pursuit of reimagining mental health and addiction care, we want to ensure the treatments we're studying are effective and accessible for as many patients as possible. Dr. Roth's extensive experience in psychiatry and pharmacology will be invaluable in progressing all of our research and development efforts." Dr. Roth noted, "Psychedelic compounds like psilocybin have some of the most robust antidepressant effects I've ever seen in Phase II studies. But not all patients are comfortable with their treatment program requiring hallucinatory trips. My research, and the perspective I'm excited to bring to MindMed's drug development programs, focuses on how we can make drugs that are maximally helpful to patients while minimizing discomfort in the treatment process." MindMed's Scientific Advisory Board is composed of a diverse group of members with expertise in psychiatry, neuroscience, and clinical development. The Scientific Advisory Board leverages decades of experience in biotechnology and psychiatry to guide MindMed's development programs. Members represent institutions such as Johns Hopkins University, New York University Langone Health, Duke University, the National Institutes of Health, Stanford University, and Massachusetts General Hospital. About MindMed MindMed is a clinical-stage psychedelic medicine biotechnology company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. MindMed is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies. MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.
